London — The Alzheimer’s Association on Monday announced a major new prevention trial, committing $100 million to test whether a drug class behind popular weight-loss medicines combined with a structured lifestyle program can reduce dementia risk in older adults before symptoms appear.
What the PROTECT-Cog study will do
Called PROTECT-Cog — Prevention of Risk fOr cogniTive dEcline through Combined Therapy — the study was revealed at the Alzheimer’s Association International Conference (AAIC 2026) in London. Investigators will test a GLP-1 receptor agonist (the same class as semaglutide, marketed as Ozempic and Wegovy) together with a proven lifestyle intervention to see whether the combination can meaningfully delay cognitive decline in people at increased risk for Alzheimer’s disease.
The trial’s emphasis is explicitly on prevention, not treatment, a strategic shift that follows setbacks in therapeutic trials. In November 2025, the high-profile EVOKE program — which evaluated semaglutide in people with early, amyloid-confirmed Alzheimer’s — failed to show a statistically significant slowing of cognitive decline despite some biomarker improvements. The association and researchers are now testing whether earlier intervention, before pathology is entrenched, may be the key.
Why researchers are combining drug and lifestyle approaches
GLP-1 receptors are found across multiple brain cell types, and preclinical and early human work suggest these drugs can reduce inflammation, support neuronal survival and improve vascular function. But experts now think timing matters: activating those pathways may be more effective before Alzheimer’s disease is advanced.
At AAIC, researchers framed the study as integrating two of the most promising prevention leads of recent years — pharmacology and behavioral change — in a single, rigorous factorial design. The intent is to learn whether the drug, the lifestyle program, or the two together produce meaningful risk reduction.
"The PROTECT-Cog Study — Prevention of Risk fOr cogniTive dEcline through Combined Therapy"
Context: what recent trials mean for prevention
The EVOKE and EVOKE+ studies enrolled 3,808 adults with early, amyloid-confirmed Alzheimer’s across 40 countries and ran for more than two years. Their negative result on clinical slowing highlighted a pharmacological constraint: by the time clinical symptoms appear, disease processes may be too advanced for GLP-1 drugs alone to change outcomes.
PROTECT-Cog aims to address that timing question by intervening earlier and coupling medication with intensive lifestyle change.
What this means for people and clinicians
For older adults worried about cognitive decline, the study offers hope that prevention strategies can be combined and tested at scale. For clinicians and policymakers, it represents a major research investment into pragmatic approaches that could inform future guidelines if successful.
- Cost committed: $100 million.
- Setting announced: AAIC 2026, London.
- Prior trial referenced: EVOKE and EVOKE+ — 3,808 participants, 40 countries, >2 years, announced November 2025.
The outcome of PROTECT-Cog will be watched closely by families, clinicians and the pharmaceutical industry. If the combination approach proves effective, it could reshape how we think about preventing Alzheimer’s disease — shifting attention from treating established illness to protecting brain health earlier in life.
